Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Market Status
  5. Filing Registration
  6. Full Approval

Full Approval

Evaluate

Thumbnail
August 01, 2023

US FDA approval and panel tracker: July 2023

Thumbnail
July 10, 2023

More, but slower, medtech approvals

If the second half maintains the pace, 2023 could see the most device approvals for a decade.

Article image
Vantage logo
July 07, 2023

Real or imagined, the Leqembi barriers emerge

Article image
Vantage logo
July 04, 2023

US FDA approval and panel tracker: June 2023

Article image
Vantage logo
June 29, 2023

Lilly goes cellular for $34m

And conveniently, Celltrans blazes a trail for cell therapies in diabetes.

Article image
Vantage logo
June 01, 2023

US FDA approval and panel tracker: May 2023

Article image
Vantage logo
May 22, 2023

Clearance makes Beta Bionics look like a target

Article image
Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Article image
Vantage logo
May 15, 2023

The waxing and waning of the speedy approval

As the FDA cools on the accelerated pathway, could biopharma’s annual approval count take a hit?

Article image
Vantage logo
May 11, 2023

Skyclarys stalls for Reata

Article image
Vantage logo
May 02, 2023

US FDA approval and panel tracker: April 2023

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up